Kandaswamy Jayaraj, MD
Endocrinology, Diabetes & Metabolism · Beaumont, TXNPI 1447258850
Payments from drug & device makers
Across 631 payments — averaging $148.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$60K
- Johnson & Johnson$20K
- Acerus Pharmaceuticals Corporation$6K
- Tandem Diabetes Care, Inc.$1K
- Boehringer Ingelheim$980
- Lilly USA, LLC$853
- plus $5K from 32 others
What the payments were for
- Consulting fees$4,9505%
- Speaking & faculty fees$75,53281%
- Travel & lodging$2,3032%
- Food & beverage$10,75511%
- Education$820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 187 | $59,871 |
| Johnson & Johnson | 44 | $19,600 |
| Acerus Pharmaceuticals Corporation | 5 | $5,616 |
| Tandem Diabetes Care, Inc. | 22 | $1,236 |
| Boehringer Ingelheim | 54 | $980 |
| Lilly USA, LLC | 56 | $853 |
| Insulet Corporation | 8 | $737 |
| Dexcom, Inc. | 55 | $706 |
| AstraZeneca(2 entities) | 27 | $451 |
| Abbott | 21 | $400 |
| Bayer | 18 | $388 |
| Radius Health, Inc. | 17 | $366 |
| BETA Bionics, Inc. | 9 | $330 |
| Sanofi-aventis U.S. LLC | 20 | $324 |
| Amgen(2 entities) | 18 | $321 |
| Medtronic(2 entities) | 14 | $292 |
| Corcept Therapeutics | 9 | $181 |
| Xeris Pharmaceuticals, Inc. | 7 | $154 |
| Merck | 8 | $124 |
| Shire North American Group Inc | 1 | $91 |
| Cequr Corporation | 1 | $71 |
| Ultragenyx Pharmaceutical Inc. | 4 | $66 |
| Amneal Pharmaceuticals LLC | 4 | $55 |
| IBSA Pharma Inc. | 4 | $54 |
| Sequel Med Tech, LLC | 2 | $54 |
| Amarin Pharma, Inc. | 3 | $53 |
| AbbVie | 2 | $39 |
| Lifescan, Inc. | 1 | $27 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Ascendis Pharma Endocrinology Inc | 1 | $22 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Novartis | 1 | $21 |
| Pfizer | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| GRT US Holding, Inc. | 1 | $11 |
| Companion Medical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$31,951
- Ozempic$25,994
- INVOKANA$18,888
- Natesto$5,586
- Omnipod$625
- t:slim X2 insulin pump$600
- iLet Bionic Pancreas$340
- t-slim insulin pump$250
- DEXCOM G7 GSS (161)$109
How this compares
$93,622 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,321 | $2,092,813 |
| MounjaroTirzepatide | 473 | $739,038 |
| Tresiba Flextouch U-200Insulin Degludec | 366 | $402,971 |
| Xigduo XrDapaglifloz Propaned/Metformin | 371 | $400,823 |
| JardianceEmpagliflozin | 348 | $336,579 |
| FarxigaDapagliflozin Propanediol | 335 | $331,644 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 222 | $225,239 |
| RybelsusSemaglutide | 102 | $166,394 |
| TrulicityDulaglutide | 72 | $107,149 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 164 | $93,060 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $74,666 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $74,534 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $74,057 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 207 | $73,333 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 40 | $50,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30, Novolog | $59,871 | $2,283,9701,498 claims |
| Lilly USA, LLCMounjaro, Trulicity | $853 | $846,187545 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $980 | $583,783591 claims |
| AstraZenecaFarxiga | $451 | $331,644335 claims |
| MerckJanuvia, Janumet Xr | $124 | $55,63842 claims |
| Johnson & JohnsonInvokana, Invokamet | $19,600 | $40,69443 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $15,7771,433 claims |
| AbbVieSynthroid | $39 | $9,397223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Beaumont
- Robert HoodBeaumont$1.5M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.